Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden

References

• Bourke L, Kirkbride P, Hooper R, et al. Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer. 2013;108(1):9–13.
   PubMed Web of Science ®Google Scholar
• Hagel E, Garmo H, Bill-Axelson A, et al. PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol. 2009;43(5):342–349.
   PubMed Web of Science ®Google Scholar
• Kuba S, Ishida M, Nakamura Y, et al. Persistence and discontinuation of adjuvant endocrine therapy in women with breast cancer. Breast Cancer. 2016;23(1):128–133.
   PubMed Web of Science ®Google Scholar
• Dhanapal V, Reeves DJ. Bone health management in prostate cancer patients receiving androgen deprivation therapy. J Oncol Pharm Pract. 2012;18(1):84–90.
   PubMedGoogle Scholar
• Chang JI, Bucci J. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report. J Med Case Rep. 2016;10(1):323.
   PubMedGoogle Scholar
• Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007;100(5):1060–1065.
   PubMed Web of Science ®Google Scholar
• Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin. 2002;52(3):154–179.
   PubMed Web of Science ®Google Scholar
• Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181(5):1998–2006.
   PubMed Web of Science ®Google Scholar
• Gomella LG, Singh J, Lallas C, et al. Hormone therapy in the management of prostate cancer: evidence-based approaches. Ther Adv Urol. 2010;2(4):171–181.
   PubMedGoogle Scholar
• Klotz L, O'Callaghan CJ, Ding K, et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. JCO. 2011;29(7_suppl):3–3.
   Web of Science ®Google Scholar
• Santoleri F, Sorice P, Lasala R. Leuprorelin and Triptorelin in the treatment of Prostate Cancer: Medication adherence, persistence and economic evaluation in five years of analysis. Int J Pharm Sci Res. 2014;1(1):101.
   Google Scholar
• Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory. Int J Epidemiol. 2016;45(1):73–82.
   PubMed Web of Science ®Google Scholar
• Cazzaniga W, Ventimiglia E, Alfano M, et al. Mini review on the use of clinical cancer registers for prostate cancer: the National Prostate Cancer Register (NPCR) of Sweden. Front Med. 2019;6:51.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956–967.
   PubMed Web of Science ®Google Scholar
• Samverkan RCI. Regarding care programs prostate cancer. 2018. [cited 2019 Apr 17]; Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/prostata/vardprogram/gallande-vardprogram-prostatacancer/1.-sammanfattning/.
   Google Scholar
• Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology. 1997;8(6):666–670.
   PubMed Web of Science ®Google Scholar
• Grundmark B, Garmo H, Zethelius B, et al. Anti-androgen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol. 2012;68(12):1619–1630.
   PubMed Web of Science ®Google Scholar
• Kozma CM, Dickson M, Phillips AL, et al. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adherence. 2013;7:509–516.
   PubMed Web of Science ®Google Scholar
• Pettersson B, Varenhorst E, Petas A, et al. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study. Eur Urol. 2006;50(3):483–489.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Eveleth JM, Shah ND, et al. Medication adherence among community-dwelling patients with heart failure. Mayo Clin Proc. 2011;86(4):273–281.
   PubMed Web of Science ®Google Scholar
• Ambardekar AV, Fonarow GC, Hernandez AF, et al. Characteristics and in-hospital outcomes for nonadherent patients with heart failure: Findings from Get With The Guidelines-Heart Failure (GWTG-HF). Am Heart J. 2009;158(4):644–652.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Phillips JM. Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort. Cancer Manag Res. 2011;3:201–209.
   PubMedGoogle Scholar
• Body JJ, von Moos R, Rider A, et al. A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe. J Bone Oncol. 2019;14:100212.
   PubMed Web of Science ®Google Scholar
• Nugin H, Folkvaljon Y, Damber JE, et al. Work-up and treatment of prostate cancer before and after publication of the first national guidelines on prostate cancer care in Sweden. Scand J Urol. 2018;52(4):277–284.
   PubMed Web of Science ®Google Scholar
• Sandler HM, Mirhadi AJ. Radical radiotherapy for prostate cancer is the 'only way to go'. Oncology. 2009;23(10):840–843.
   PubMed Web of Science ®Google Scholar
• Lycken M, Garmo H, Adolfsson J, et al. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: A population-based study. Eur J Cancer. 2014;50(10):1789–1798.
   PubMed Web of Science ®Google Scholar
• Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341(24):1781–1788.
   PubMed Web of Science ®Google Scholar
• Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3(Suppl 3):S10–S14.
   PubMedGoogle Scholar
• Jin J, Sklar GE, Min Sen Oh V, et al. Factors affecting therapeutic compliance: a review from the patient’s perspective. TCRM. 2008;4(1):269–286.
   Google Scholar